Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More